Posenacaftor

Small moleculeexperimental

Clinical trial activity

4 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Apr 10, 2017 (NCT03140527)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2024

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Cc1c(-c2cc(C(=O)O)c3c(O[C@H](C)C4CCOCC4)ccc(C)c3n2)oc2ccccc12
Mol. weight
445.52 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • pti-801
  • pti-801

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06468527Phase 2Jun 3, 2024European Union, Utrecht University
NCT03500263Phase 1Jan 30, 2018Proteostasis Therapeutics
NCT03251092Phase 1Jul 17, 2017ICON, Medical University of South Carolina, Proteostasis Therapeutics
NCT03140527Phase 1Apr 10, 2017Proteostasis Therapeutics
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Proteostasis TherapeuticsFor profit3312017
European UnionGovernment1012024
ICONFor profit1012017
Medical University of South CarolinaAcademic/Hospital1012017
Utrecht UniversityAcademic/Hospital1112024
5 organizations
Page 1 / 1